No connection

Search Results

ACLX vs HQY

ACLX
Arcellx, Inc.
BEARISH
Price
$114.39
Market Cap
$6.69B
Sector
Healthcare
AI Confidence
88%
HQY
HealthEquity, Inc.
NEUTRAL
Price
$77.96
Market Cap
$6.66B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ACLX
--
HQY
31.69
Forward P/E
ACLX
-71.6
HQY
14.6
P/B Ratio
ACLX
16.47
HQY
3.15
P/S Ratio
ACLX
300.17
HQY
5.07
EV/EBITDA
ACLX
-25.53
HQY
15.08

Profitability

Gross Margin
ACLX
0.0%
HQY
69.52%
Operating Margin
ACLX
-3850.24%
HQY
21.64%
Profit Margin
ACLX
0.0%
HQY
16.38%
ROE
ACLX
-53.42%
HQY
10.19%
ROA
ACLX
-24.05%
HQY
5.99%

Growth

Revenue Growth
ACLX
-89.2%
HQY
7.3%
Earnings Growth
ACLX
--
HQY
92.4%

Financial Health

Debt/Equity
ACLX
0.13
HQY
0.48
Current Ratio
ACLX
4.43
HQY
3.27
Quick Ratio
ACLX
4.32
HQY
2.82

Dividends

Dividend Yield
ACLX
--
HQY
--
Payout Ratio
ACLX
0.0%
HQY
0.0%

AI Verdict

ACLX BEARISH

ACLX exhibits severe financial distress despite a strong technical trend and recent insider selling. The Piotroski F-Score of 1/9 indicates extremely weak financial health, with negative profitability metrics across all dimensions—operating margin at -3850.24%, ROE at -53.42%, and a revenue decline of -89.20% YoY. The absence of an Altman Z-Score raises bankruptcy risk concerns, while the Graham Number and intrinsic value are unavailable, suggesting no reliable defensive valuation. The stock trades at a massive premium with a Price/Sales of 300.17 and Forward P/E of -71.60, reflecting speculative growth expectations rather than fundamentals.

Strengths
Strong technical trend (10/100) indicating short-term bullish momentum
Recent quarters have shown positive earnings surprises (e.g., +69.5%, +184.0%)
High insider activity in recent quarters (though all sales)
Risks
Piotroski F-Score of 1/9 signals extreme financial weakness and poor operational efficiency
Negative operating margin (-3850.24%) and zero profit margin indicate unsustainable business model
Revenue declined 89.20% YoY, signaling core business contraction
HQY NEUTRAL

HQY presents a stark divergence between strong fundamental earnings performance and bearish market sentiment. The company maintains a stable financial health profile with a Piotroski F-Score of 4/9 and excellent liquidity (Current Ratio 3.27). While the current price of $77.96 trades at a premium to its intrinsic value ($72.57) and Graham Number ($37.04), the Forward P/E of 14.60 suggests significant expected earnings expansion. However, the bullish fundamental outlook is heavily countered by a 0/100 technical trend and consistent insider selling.

Strengths
Explosive YoY earnings growth of 92.40%
Strong liquidity position with a current ratio of 3.27
Impressive gross margins of 69.52%
Risks
Strongly bearish technical trend (0/100)
Net insider selling activity across multiple executives
Current price exceeds growth-based intrinsic value ($72.57)

Compare Another Pair

ACLX vs HQY: Head-to-Head Comparison

This page compares Arcellx, Inc. (ACLX) and HealthEquity, Inc. (HQY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile